Clinical application of CSF biomarkers for Alzheimer's disease: From rationale to ratios
FH Bouwman, GB Frisoni, SC Johnson… - Alzheimer's & …, 2022 - Wiley Online Library
Biomarker testing is recommended for the accurate and timely diagnosis of Alzheimer's
disease (AD). Using illustrative case narratives we consider how cerebrospinal fluid (CSF) …
disease (AD). Using illustrative case narratives we consider how cerebrospinal fluid (CSF) …
Clinical considerations in early-onset cerebral amyloid angiopathy
Cerebral amyloid angiopathy (CAA) is an important cerebral small vessel disease
associated with brain haemorrhage and cognitive change. The commonest form, sporadic …
associated with brain haemorrhage and cognitive change. The commonest form, sporadic …
[HTML][HTML] Validation of the LUMIPULSE automated immunoassay for the measurement of core AD biomarkers in cerebrospinal fluid
J Gobom, L Parnetti, P Rosa-Neto… - Clinical Chemistry and …, 2022 - degruyter.com
Objectives The core cerebrospinal fluid (CSF) biomarkers; total tau (tTau), phospho-tau
(pTau), amyloid β 1-42 (Aβ 1-42), and the Aβ 1-42/Aβ 1-40 ratio have transformed …
(pTau), amyloid β 1-42 (Aβ 1-42), and the Aβ 1-42/Aβ 1-40 ratio have transformed …
[HTML][HTML] Diagnostic biomarkers of amyloid and tau pathology in Alzheimer's disease: An overview of tests for clinical practice in the United States and Europe
L Iaccarino, SC Burnham, G Dell'Agnello… - The Journal of …, 2023 - Springer
Amyloid and tau biomarkers for Alzheimer's disease are widely recognized diagnostic tools
for the identification of Alzheimer's disease pathology antemortem and are recommended by …
for the identification of Alzheimer's disease pathology antemortem and are recommended by …
[HTML][HTML] Accuracy of plasma Aβ40, Aβ42, and p-tau181 to detect CSF Alzheimer's pathological changes in cognitively unimpaired subjects using the Lumipulse …
F Martínez-Dubarbie, A Guerra-Ruiz… - Alzheimer's Research & …, 2023 - Springer
Background The arrival of new disease-modifying treatments for Alzheimer's disease (AD)
requires the identification of subjects at risk in a simple, inexpensive, and non-invasive way …
requires the identification of subjects at risk in a simple, inexpensive, and non-invasive way …
Distinguishing frontotemporal lobar degeneration tau from TDP-43 using plasma biomarkers
KAQ Cousins, LM Shaw, A Chen-Plotkin… - JAMA …, 2022 - jamanetwork.com
Importance Biomarkers are lacking that can discriminate frontotemporal lobar degeneration
(FTLD) associated with tau (FTLD-tau) or TDP-43 (FTLD-TDP). Objective To test whether …
(FTLD) associated with tau (FTLD-tau) or TDP-43 (FTLD-TDP). Objective To test whether …
[HTML][HTML] Concentrations of S100B and neurofilament light chain in blood as biomarkers for checkpoint inhibitor–induced CNS inflammation
S Bjursten, Z Zhao, H Al Remawi, M Studahl… - …, 2024 - thelancet.com
Background Cancer treatment with immune checkpoint inhibition (ICI) can cause immune-
related adverse events in the central nervous system (CNS irAE). There are no blood …
related adverse events in the central nervous system (CNS irAE). There are no blood …
Optimal combinations of CSF biomarkers for predicting cognitive decline and clinical conversion in cognitively unimpaired participants and mild cognitive impairment …
INTRODUCTION Our objective was determining the optimal combinations of cerebrospinal
fluid (CSF) biomarkers for predicting disease progression in Alzheimer's disease (AD) and …
fluid (CSF) biomarkers for predicting disease progression in Alzheimer's disease (AD) and …
CSF Alzheimer Disease Biomarkers: Time-Varying Relationships With MCI Symptom Onset and Associations With Age, Sex, and ApoE4
BD Greenberg, C Pettigrew, A Soldan, J Wang… - Neurology, 2022 - AAN Enterprises
Background and Objectives This study aimed to examine whether baseline CSF measures
of Alzheimer disease (AD)–related pathology are associated with the time to onset of mild …
of Alzheimer disease (AD)–related pathology are associated with the time to onset of mild …
[HTML][HTML] Is plasma amyloid-β 1–42/1–40 a better biomarker for Alzheimer's disease than AβX–42/X–40?
Background A reduced amyloid-β (Aβ) 42/40 peptide ratio in blood plasma represents a
peripheral biomarker of the cerebral amyloid pathology observed in Alzheimer's disease …
peripheral biomarker of the cerebral amyloid pathology observed in Alzheimer's disease …